Penn Medicine
Continuing Medical and Interprofessional Education

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

The staff in the Office of Continuing Medical and Inter-Professional Education at Penn Medicine and the listed Planning Committee members (*) for this activity have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity. In accordance with ACCME Standards, all individuals in control of content are required to disclose any financial relationships with ineligible companies that occur within the past 24 months, regardless of whether the relationship is ongoing or has ended.

The following faculty and Planning Committee Members (*) have disclosed that they have no financial relationships with any ineligible companies related to the content of this educational activity.

Jen Bremer*
Kellie Beumer, MBA*
Frederic D. Bushman, PhD
Melissa Cadnapaphornchai, MD, PhD
Jennifer Harding, MPA*
Ype Jong, PhD

The following faculty and Planning Committee member(s)* have disclosed all financial relationships with ineligible companies. All relevant financial relationships with ineligible companies are listed below. All relevant financial relationships have been mitigated.

Rebecca Ahrens-Nicklas, MD, PhD*
Advisor-AskBio|Advisor-LatusBio

Richard J. Dyke, PharmD
Consulting Fee-Neurogene (Relationship has ended)|Honoraria-CPE Consultants (Relationship has ended)|Honoraria-Red Nucleus (Relationship has ended)

Richard S. Finkel, MD
Grant or research support-Biogen, Genentech, Novartis, Roche, Scholar Rock, Sarepta, Insmed|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Biogen, Ionis, Novartis, Roche, Scholar Rock, Sarepta, n-Lorem Fdn, Gemma Bioscience, Solid

Kevin M. Flanigan, MD*
Grant or research support-Ultragenyx|Consulting Fee-AskBio|Consulting Fee-NS Pharma (Relationship has ended)|Consulting Fee-Precision Biosciences (Relationship has ended)|Consulting Fee-Satellos (Relationship has ended)|Stock options in any amount of a publicly traded or privately owned (non-publicly traded) company-Armatus|Consulting Fee-Avidity (Relationship has ended)|Consulting Fee-Dyne Therapeutics (Relationship has ended)|Grant or research support-Dyne|Consulting Fee-Regenxbio (Relationship has ended)|Consulting Fee-Solid Biosciences (Relationship has ended)

Lindsey George, MD*
Paid consultant-Regeneron Pharmaceuticals, Inc.

Susan Matesanz, MD
Advisor-Dyne Therapeutics|Consulting Fee-Avidity Biosciences|Advisor-Sarepta

Penn Medicine
Continuing Medical and Interprofessional Education

Kiran Musunuru, MD, PhD, ML

Paid consultant-Verve Therapeutics|Stocks in any amount, excluding diversified mutual funds of a publicly traded company-Verve Therapeutics (Relationship has ended)|Stock options in any amount of a publicly traded or privately owned (non-publicly traded) company-Variant Bio|Grant or research support-Nava Therapeutics|Grant or research support-Beam Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Capstan Therapeutics (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lexeo Therapeutics (Relationship has ended)

Ben Samelson-Jones, MD*

Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Membership on Advisory Committees or Review Panels, Board Membership, etc.-CSL Behring (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novo Nordisk (Relationship has ended)|Grant or research support-Novo Nordisk|Paid consultant-Voyager|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron Pharmaceuticals, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Intellia (Relationship has ended)

Raymond Wang, MD*

Grant or research support-Biomarin Pharmaceutical|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Denali Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-JCR Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-REGENXBIO, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Green Cross Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Otsuka Pharmaceuticals

*Planning Committee Members

**Financial relationships are defined as any relationship, in any amount, with an ineligible company. An ineligible company is defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are defined as relevant if the educational content is related to the business lines or products of the ineligible company.